SynBiotic SE (FRA:SBX)

Germany flag Germany · Delayed Price · Currency is EUR
3.215
+0.115 (3.71%)
At close: Jun 6, 2025, 10:00 PM CET
-60.21%
Market Cap 21.86M
Revenue (ttm) 3.86M
Net Income (ttm) -10.63M
Shares Out n/a
EPS (ttm) -2.24
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 481
Average Volume 2,584
Open 3.075
Previous Close 3.100
Day's Range 3.075 - 3.295
52-Week Range 2.550 - 9.260
Beta n/a
RSI 48.99
Earnings Date May 16, 2025

About SynBiotic SE

SynBiotic SE engages in the research and development, production, and marketing of cannabinoid and terpene-based solutions to for pain, sleep deprivation, and anxiety. It also offers hemp, cannabinoids, dietary supplements, and cosmetic products; medical cannabis products; and cannabis products for recreational use under the Hempamed, Princess Stardust, The Hempany, and Hempamed Rx brand names. The company was formerly known as Ledgertech SE and changed its name to SynBiotic SE. SynBiotic SE was incorporated in 2024 and is based in Munich, Germ... [Read more]

Industry Pharmaceutical Preparations
Founded 2024
Employees 55
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol SBX
Full Company Profile

Financial Performance

In 2023, SynBiotic SE's revenue was 3.86 million, a decrease of -52.71% compared to the previous year's 8.17 million. Losses were -10.63 million, -56.36% less than in 2022.

Financial Statements

News

EQS-DD: SYNBIOTIC SE: HempConsult GmbH, Lending (free of charge) of 50,000 shares as part of a securities lending programme.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 23.04.2025 / 09:22 CET/CEST The issuer is solely responsi...

6 weeks ago - Wallstreet:Online